New hope for advanced cancer: IMC-002 enters human trials
NCT ID NCT05276310
First seen Apr 26, 2026 · Last updated May 16, 2026 · Updated 6 times
Summary
This early-stage study tests a new drug called IMC-002 in about 62 adults with advanced solid tumors that no longer respond to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and whether it can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center, Republic of Korea
COMPLETEDSeoul, South Korea
-
National Cancer Center
ACTIVE_NOT_RECRUITINGGoyang-si, South Korea
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact
Conditions
Explore the condition pages connected to this study.